Oktay Halit Aktepe1, Fatma Gundogdu2, Kemal Kosemehmetoglu2, Haci Hasan Yeter3, Sercan Aksoy4, Deniz Can Guven4, Taha Koray Sahin5, Deniz Yuce6, Neyran Kertmen4, Omer Dizdar6, Suayib Yalcin4, Mustafa Erman6. 1. Department of Medical Oncology, Bolu Abant Izzet Baysal University, 14030, Bolu, Turkey. droktayaktepe@hotmail.com. 2. Department of Pathology, Faculty of Medicine, Hacettepe University, Ankara, Turkey. 3. Department of Nephrology, Faculty of Medicine, Gazi University, Ankara, Turkey. 4. Department of Medical Oncology, Hacettepe University Cancer Institute, Ankara, Turkey. 5. Department of Internal Medicine, Faculty of Medicine, Hacettepe University, Ankara, Turkey. 6. Department of Preventive Oncology, Hacettepe University Cancer Institute, Ankara, Turkey.
Abstract
BACKGROUND: The association of thrombospondin type 1 domain-containing 7A (THSD7A) expression, a novel angiogenesis-related marker, with survival outcomes of tumors including renal cell carcinoma (RCC) remains to be clarified. Therefore, we investigated the impact of THSD7A on outcomes of metastatic RCC (mRCC) patients treated with targeted therapy. METHODS: A total of 86 mRCC patients were included. The expression of THSD7A in nephrectomy material of the patients was assessed by immunohistochemistry and expression patterns were categorized into two groups: negative (no staining) and positive. Univariable and multivariable Cox regression models evaluated the impact of THSD7A expression on progression free survival (PFS) and overall survival (OS) of the patients. RESULTS: THSD7A expression was determined in 77.9% of the patients. Kaplan-Meier analyses showed that while the patients with THSD7A expression had significantly inferior OS times than those with negative THSD7A expression (19.9 months vs. 52.2 months, P = 0.024, respectively), there was no association between THSD7A expression and PFS. The univariate analyses demonstrated that the significant variables in predicting OS were presence of bone metastasis (P = 0.030), THSD7A expression (P = 0.028), and International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) scoring system (P < 0.001). However, applying multivariate analyses, the independent variables in predicting OS were THSD7A expression (HR: 2.639, P = 0.037) and IMDC scoring system (P < 0.001). CONCLUSION: We revealed that THSD7A expression was associated with OS of mRCC patients treated with targeted therapy. There might be an important link between THSD7A expression and resistance to targeted therapy.
BACKGROUND: The association of thrombospondin type 1 domain-containing 7A (THSD7A) expression, a novel angiogenesis-related marker, with survival outcomes of tumors including renal cell carcinoma (RCC) remains to be clarified. Therefore, we investigated the impact of THSD7A on outcomes of metastatic RCC (mRCC) patients treated with targeted therapy. METHODS: A total of 86 mRCC patients were included. The expression of THSD7A in nephrectomy material of the patients was assessed by immunohistochemistry and expression patterns were categorized into two groups: negative (no staining) and positive. Univariable and multivariable Cox regression models evaluated the impact of THSD7A expression on progression free survival (PFS) and overall survival (OS) of the patients. RESULTS: THSD7A expression was determined in 77.9% of the patients. Kaplan-Meier analyses showed that while the patients with THSD7A expression had significantly inferior OS times than those with negative THSD7A expression (19.9 months vs. 52.2 months, P = 0.024, respectively), there was no association between THSD7A expression and PFS. The univariate analyses demonstrated that the significant variables in predicting OS were presence of bone metastasis (P = 0.030), THSD7A expression (P = 0.028), and International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) scoring system (P < 0.001). However, applying multivariate analyses, the independent variables in predicting OS were THSD7A expression (HR: 2.639, P = 0.037) and IMDC scoring system (P < 0.001). CONCLUSION: We revealed that THSD7A expression was associated with OS of mRCC patients treated with targeted therapy. There might be an important link between THSD7A expression and resistance to targeted therapy.
Authors: Gladell P Paner; Mahul B Amin; Isabel Alvarado-Cabrero; Andrew N Young; Hans J Stricker; Holger Moch; Robert H Lyles Journal: Am J Surg Pathol Date: 2010-09 Impact factor: 6.394
Authors: Robert J Motzer; Eric Jonasch; M Dror Michaelson; Lakshminarayanan Nandagopal; John L Gore; Saby George; Ajjai Alva; Naomi Haas; Michael R Harrison; Elizabeth R Plimack; Jeffrey Sosman; Neeraj Agarwal; Sam Bhayani; Toni K Choueiri; Brian A Costello; Ithaar H Derweesh; Thomas H Gallagher; Steven L Hancock; Christos Kyriakopoulos; Chad LaGrange; Elaine T Lam; Clayton Lau; Bryan Lewis; Brandon Manley; Brittany McCreery; Andrew McDonald; Amir Mortazavi; Phillip M Pierorazio; Lee Ponsky; Bruce G Redman; Bradley Somer; Geoffrey Wile; Mary A Dwyer; Lydia J Hammond; Griselda Zuccarino-Catania Journal: J Natl Compr Canc Netw Date: 2019-11-01 Impact factor: 11.908
Authors: Phillip R Stahl; Elion Hoxha; Thorsten Wiech; Cornelia Schröder; Ronald Simon; Rolf A K Stahl Journal: Genes Chromosomes Cancer Date: 2017-02-06 Impact factor: 5.006
Authors: Daniel Y C Heng; Wanling Xie; Meredith M Regan; Mark A Warren; Ali Reza Golshayan; Chakshu Sahi; Bernhard J Eigl; J Dean Ruether; Tina Cheng; Scott North; Peter Venner; Jennifer J Knox; Kim N Chi; Christian Kollmannsberger; David F McDermott; William K Oh; Michael B Atkins; Ronald M Bukowski; Brian I Rini; Toni K Choueiri Journal: J Clin Oncol Date: 2009-10-13 Impact factor: 44.544